Home ›
Uterine Cancer Trials ›
NCT05316935
GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients
To investigate the efficacy of GnRHa plus letrozole vs Diane-35 plus metformin in non-obese progestin-insensitive early-stage endometrial cancer (EEC) and atypical hyperplasia(EAH) patients asking for conservative treatment.
Trial Details
NCT ID NCT05316935
Phase PHASE2 / PHASE3
Sponsor Xiaojun Chen
Status RECRUITING
Cancer Type Uterine Cancer
Interventions GnRHa Letrozole 2.5mg Diane-35 MET
Locations (sample) Shanghai, Shanghai Municipality, China|31.22222,121.45806 Shanghai, Shanghai Municipality, China|31.22222,121.45806
Key Eligibility Criteria
Have a confirmed initial pathological diagnosis based upon hysteroscopy: histologically prove EAH or well-differentiated EEC G1 without myometrial … BMI\<30kg/m2 No signs of suspicious extrauterine involvement on enhanced magnetic resonance imaging (MRI) or enhanced computed tomography (CT) or ultrasound Using progestin, any of the following therapy, as first-line treatment:
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Uterine Cancer Trials on Trialify →